First thalidomide clinical trial in multiple myeloma: a decade

Ítems similars

• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  per: van Rhee, Frits, et al.
  Publicat: (2010)
• Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
  per: Barlogie, Bart, et al.
  Publicat: (2008)
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
  per: Nair, Bijay, et al.
  Publicat: (2010)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  per: Hoering, Antje, et al.
  Publicat: (2009)
• Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
  per: Barlogie, Bart, et al.
  Publicat: (2008)